ATL1102 Phase IIa Multiple Sclerosis Trial Update
PipelineReview.com (press release) - Barcelona,Spain
The Company is currently conducting this 80 patient trial to assess the safety and efficacy of ATL1102 in relapsing-remitting MS patients in Poland, ...
See all stories on this topic

Disease activity increases after multiple sclerosis patients stop natalizumab
News-Medical-Net Thu, 13 Sep 2007 5:28 AM PDT
People with multiple sclerosis who stop taking the drug natalizumab may experience a rebound increase in disease activity, according to a study published September 12, 2007, in the online edition of Neurology, the medical journal of the American Academy of Neurology.

Stopping Tysabri May Worsen MS
HealthDay via Yahoo! News Thu, 13 Sep 2007 9:01 AM PDT
THURSDAY, Sept. 13 (HealthDay News) -- People suffering from multiple sclerosis who stopped taking the controversial drug Tysabri experienced a resurgence of brain lesions associated with their disease, researchers report.

Stopping Tysabri May Worsen MS
KOLD News 13 Tuscon Thu, 13 Sep 2007 11:11 AM PDT
By Amanda Gardner , HealthDay Reporter THURSDAY, Sept. 13 (HealthDay News) -- People suffering from multiple sclerosis who stopped taking the controversial drug...

New understanding of immune infertility
News-Medical-Net Thu, 13 Sep 2007 4:27 AM PDT
Most of us have never heard of immune infertility, yet it prevents many prospective parents from conceiving. Immune infertility is one of 80 autoimmune disorders, a group that includes better-known diseases like Multiple Sclerosis and Type 1 Diabetes.